Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered in a prime-boost regimen among Chinese infants: a randomized, double blind phase III clinical trial

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered in a prime-boost regimen among Chinese infants: a randomized, double blind phase III clinical trial

This study aimed to evaluate the immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13). In total, 1200 infants were randomized into two groups with a 1:1 allocation and received a three-dose series of tested PCV13 or control PCV13 at ages 2, 4 and 6 months, respectively, an...

Full description

Bibliographic Details
Main Authors: Wenjuan Wang, Qi Liang, Jiahong Zhu, Junxia Zhang, Junsheng Chen, Sulan Xie, Yuemei Hu, Guifan Li
Format: Article
Language:English
Published: Taylor & Francis Group 2022-01-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
immunogenicity
safety
pcv
13-valent pneumococcal conjugate vaccine
infants
Online Access:http://dx.doi.org/10.1080/21645515.2021.2019498

Internet

http://dx.doi.org/10.1080/21645515.2021.2019498

Similar Items